Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Dec 9;79:102995. doi: 10.1016/j.eclinm.2024.102995

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 The Authors

This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

PMC Copyright notice

Fig. 1 — Vaccine effectiveness¹against COVID-19 hospitalization in SARI patients who received at least one dose of BNT162b2 XBB.1.5-adapted vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season.¹Vaccine effectiveness estimates are adjusted for date of symptom onset, age, sex, and number of chronic conditions. ²‘Never vaccinated’ subjects were excluded when calculating the median (IQR) of time since last vaccine dose in the unexposed group (patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season). ³The categories “Cancer” and “Immunodeficiency” among chronic conditions are counted as separate types of chronic conditions in all adjusted VE estimates. Here, the VE estimate among participants having “Immunodeficiency or cancer” is provided as a composite. ⁴The categories “0” and “1” among the number of chronic conditions are counted as separate categories of number of chronic conditions in all adjusted VE estimates. Here, the VE estimate among participants having “0–1”chronic conditions is provided as a composite.